A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis versus Factor VIII Prophylaxis in People with Hemophilia A without Inhibitors

F. Hoffmann La Roche Ltd0 个研究点目标入组 2 人开始时间: 2026年7月31日最近更新: 2026年8月3日

适应症

试验速览

暂无简介。

•Diagnosis of severe (FVIII:C <1 IU/dL [International Unit per decilitre]) or moderate (FVIII:C between =1 IU/dL and =5 IU/dL) congenital hemophilia A without inhibitors against FVIII
•No documented inhibitor (i.e., <0.6 BU/mL [Bethesda unit per millilitre]), FVIII half-life =6 hours, or FVIII recovery >66% in the last 3 years prior to screening
•Documented historical negative test for FVIII inhibitor (i.e., <0.6 BU/mL) within 12 months prior to enrollment
•Documentation of the details of prophylactic and episodic FVIII treatment and of the number and type of bleeding episodes for at least the last 6 months prior to screening
•Agreement to adhere to the contraception requirements (for potential participants with childbearing potential)

•Sensitivity to any of the study investigations, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study
•Use of systemic immunomodulators (e.g., interferon or rituximab) at the time of enrollment or planned use during the study, except for anti-retroviral therapy to treat HIV
•Planned surgery (excluding minor procedures such as non-molar tooth extraction, incision and drainage) during the study
•History or presence of an abnormal ECG that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third- degree atrioventricular heart block) or ECG evidence or clinical history of prior myocardial infarction
•Refusal to accept plasma-derived and/or blood product transfusion support in an emergency scenario
•History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)

发起方